Eight More Years: US Supreme Court Sinks Sandoz’ Hopes On Enbrel
Erelzi Biosimilar Etanercept Is Now Barred Until 2029 In The US
Executive Summary
Sandoz’ arguments urging the US Supreme Court to review patent litigation around Amgen’s Enbrel have fallen on deaf ears, blocking a route to market for biosimilar etanercept until 2029 in the US.
You may also be interested in...
‘Rapid Adoption’ Expected For US Humira Biosimilars
Uptake is expected to be “rapid” once Humira biosimilars launch in the US, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen. Meanwhile, milestone first approvals for interchangeable and ophthalmic biosimilars show that the US biosimilars market is moving in the right direction, he tells Generics Bulletin in an exclusive Q&A.
Xbrane Joins Forces With Contract Manufacturer For Cimzia Biosimilar
Sweden’s Xbrane Biopharma has secured a manufacturing partner in its native Scandinavia, Denmark’s AGC Biologics, to help complete key steps for its proposed Xcimzane (certolizumab pegol) biosimilar to Cimzia ahead of Phase I and Phase III clinical trials.
Cigna Infliximab Users Get $500 To Switch To Biosimilars
Program aims to share rebate savings from preferred drugs, ease treatment disruptions. Products like Remicade covered under medical benefits require new kinds of incentives for switching.